Press release Oncology Venture issues 287,500 new shares in connection with a debt conversion

NEXT STORY
Amunix Pharmaceuticals Announces Technology Licensing Agreement with Roche to Advance Novel Therapeutics Outside Oncology
PREV STORY
Affimed Announces Appointment of Andreas Harstrick, M.D., as Chief Medical Officer
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Three Abstracts on Dosing Regimens of Cellectar’s CLR 131 in a Variety of Tumor Types Published in the 2017 ASCO Annual Meeting Proceedings

MADISON, Wis., May 18, 2017 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB), (the “company”), ...

author_avatar
NASDAQ Market News

Innovation Pharmaceuticals Announces $7 million Milestone Funding Agreement with Aspire Capital

$2 million Received on Signing the AgreementBEVERLY, Mass., June 28, 2018 (GLOBE NEWSWIRE) -- ...

author_avatar
NASDAQ Market News

At the Meet Novartis Management investor event, Novartis highlights focus on innovation and productivity; expects the next growth phase to begin in 2018

Building depth across key therapeutic areas with 12 potential blockbusters in late stage development ...

author_avatar
NASDAQ Market News